Skip to main content

Market Overview

Proteostasis Therapeutics Shares Initiated With Buy, $15 Price Target

Share:

HC Wainwright’s Andrew S. Fein initiated coverage of Proteostasis Therapeutics Inc (NASDAQ: PTI) with a Buy rating and a price target of $15. The company develops disease-modifying therapeutics for diseases related to protein processing.

At a time when combination-driven treatments are being preferred, Proteostatis Therapeutics possess an attractive asset and platform, including a mechanism of action that increases mRNA stability and could be synergistic to all “corrector potentiator combinations in clinical development,” analyst Andrew Fein mentioned.

The company’s assets also include a preclinically-superior in-house triple corrector potentiator amplifier combination, due to enter the clinic as early as 1H17, Fein added.

Amplifiers And Their Synergistic Benefits

The limited clinical benefit of Orkambi in the F508del homozygous population has brightened the prospects for add-on agents that either boost the benefit in responders and/or provide an opportunity to induce response in the non-responder population, Fein stated.

Although several types of amplifiers are available in the market, Proteostatis’ CFTR “amplifier” PTI-428 offers significant synergistic and additive benefit. The analyst wrote, “PTI-428 emerged as the lead candidate from a series of compounds identified through the DRT platform that stabilize CFTR transcripts, increasing CFTR mRNA half life and protein levels.”

Fein expects several near-term catalysts, including Phase I biomarker data for CFTRmRNA and possible efficacy surrogate data, in 2Q16. The Phase 2 efficacy data for FEV1 is also possible by 4Q16 or 1Q17.

Latest Ratings for PTI

DateFirmActionFromTo
Nov 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Oct 2018Piper SandlerInitiates Coverage OnOverweight
Oct 2018RBC CapitalUpgradesSector PerformOutperform

View More Analyst Ratings for PTI

View the Latest Analyst Ratings

 

Related Articles (PTI)

View Comments and Join the Discussion!

Posted-In: Andrew S. Fein HC WainwrightAnalyst Color Long Ideas Initiation Analyst Ratings Trading Ideas

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com